| Similar Articles |
|---|
 |
Scientific American
July 2006
JR Minkel |
Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive.   |
Fast Company
December 2009
Ryan Blitstein |
Which Poverty-Fighting Policies Work? J-PAL Has the Answer A global league of economists called J-PAL is deploying its experimental methods and one all-powerful asset -- data -- to explain human behavior, change how we help the poor, and try to save the world. |
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell |
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. |
Scientific American
November 21, 2005
JR Minkel |
Trials for the Poor Researchers hope randomized trials will help develop better antipoverty programs. |
Finance & Development
June 1, 2005
Cohen & Bloom |
Cultivating Minds Educating all the world's children well is not only urgent but also feasible within the next few decades. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
BusinessWeek
July 2, 2010
Maureen Tkacik |
The Pragmatic Rebels The financial crisis blew a hole in big-think economics, raising the profile of a new breed of skeptical empiricists committed to assiduous testing and tangible results in development economics, no matter how tiny. |
Finance & Development
December 1, 2007 |
Is the Global Health System Broken Three points of view on how the global health system can be improved: Making Markets Work by Joe Cerrell... Finding a Unified Vision by Helen Gayle and J. Stephen Morrison... Targeting the Health MDGs by Tore Godal... |
Finance & Development
March 1, 2003
Jeremy Clift |
The Lab Man How experimental economics emerged from the shadows: an interview with Nobel Prize winner Vernon L. Smith |
HBS Working Knowledge
March 1, 2004
Martha Lagace |
Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
Fast Company
December 2009 |
J-Pal's Most Provocative Inquiries J-PAL members hope their findings will inspire smarter anti-poverty policy. Here, a look at some of their most provocative inquiries. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
Pharmaceutical Executive
October 1, 2011 |
The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work. |
Finance & Development
March 1, 2003 |
Letters to the Editor Poverty debate... IMF loans to autocratic regimes... Measuring potential debt... Odious debt... etc. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
| Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
Pharmaceutical Executive
June 1, 2005
Seth Berkley |
Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer. |
Smithsonian
November 2005 |
35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world. |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
